Voices of Biotech
Podcast: MilliporeSigma says education vital to creating unbreakable chain for sustainability
MilliporeSigma discusses the importance of people, education, and the benefits of embracing discomfort to bolster sustainability efforts.
- Sponsored Content
- Manufacturing
BPI Contributor
April 30, 2020
20 Min View
Date: Apr 30, 2020
Duration: 20 Min
Sponsored by WuXi Advanced Therapies
This webcast features: Juan Lagos and Steve Tottey, Associate Directors of Upstream and Downstream Process Development, WuXi Advanced Therapies
Developing innovative advanced therapies is one of our greatest opportunities to dramatically improve patients’ lives. WuXi Advanced Therapies launched a new world-class adenoassociated virus (AAV) vector suspension platform that complements integrated capabilities enabling cell and gene therapies to be developed, manufactured, and released faster and with greater predictability globally.
In this webinar, we will discuss our recent technical advancement on efficient viral vector manufacturing process development. From cell line development, to suspension culture of HEK293 cells, to transfection, to cell culture optimization and purification process development, a series of progress were implemented, reaching high viral titer with greater robustness, scalability, and predictability. The new platforms allow us to move clients with plasmids from feasibility through GMP manufacturing efficiently.
Key Lessons Learned:
Achieve greater scalability, reproducibility, and predictability
Develop an efficient process with high titer, yield, and quality
Discover an AAV vector suspension platform with fully integrated in-process and release testing
Just fill out the form below to watch the recorded webcast now.
About the Author(s)
You May Also Like
Upcoming Webcasts
Jun 17 - Jun 20, 2024
Jun 17 - Jun 20, 2024
Our Biopharmaceutical School is the perfect course to gain a well-rounded understanding of the Biopharmaceutical industry. Over three days, you will understand the principle steps in the biopharmaceutical lifecycle, including: raw material selection, up and downstream processes and core technology. Additionally, you will be familiarised with the latest industry trends, including Industry 4.0, and how these are likely to impact the industry’s evolution.
Through a combination of sessions led by experts from the likes of GSK and Pall Biotech, as well as group discussions with your peers, you will learn how to bring a biopharmaceutical drug to market. Each day will be chaired by a different member of the BioProcess International Academy faculty and there will also be time for networking and Q&As with the experts.
Learn More